AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17651893 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0
Study 17651893 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0
Study 17651893 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 0
Study 17651893 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 16246772 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15%
Number of subjects: 80
Study 16246772 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 80
Study 11873008 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg), one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Number of subjects: 662
Study 11873008 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Number of subjects: 662
Study 11873008 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) among women with CD4 cell counts < 500/ml
Number of subjects: 662
Study 11873008 — intervention group
Group type: COMPARATOR
Intervention: Placebo among women with CD4 cell counts < 500/ml
Number of subjects: 662
Study 11873008 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) among women with CD4 cell counts >= 500/ml
Number of subjects: 662
Study 11873008 — intervention group
Group type: COMPARATOR
Intervention: Placebo among women with CD4 cell counts >= 500/ml
Number of subjects: 662
Study 9864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20‐30 mg/day) added to selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 30
Study 9864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20‐30 mg/day) added to clomipramine
Number of subjects: 30
Study 9864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone augmentation therapy
Number of subjects: 30
Study 8680900 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day mesalazine
Number of subjects: 169
Study 8680900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/day mesalazine
Number of subjects: 169
Study 2220604 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (daily doses ranged from 2.5 to 40 mg)
Number of subjects: 253
Study 2220604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 2220604 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253
Study 477676 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Number of subjects: 106
Study 477676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Number of subjects: 106
Study 31988253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercises on a cycle ergometer combined with CPAP
Number of subjects: 31
Study 31988253 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises and passive mobilization in the sitting position, progressing to active exercises, ambulation, and stair training
Number of subjects: 31
Study 31079124 — intervention group
Group type: EXPERIMENTAL
Intervention: Various laryngeal grades based on Cormack and Lehane
Number of subjects: 405
Study 31079124 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the patient, opening of mouth, retrognathia, overbite, overjet, limited neck extension, thyromental distance, Mallampati grade, macroglossia
Number of subjects: 405
Study 31079124 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI, neck circumference, neck aches, jaw aches, tonsil size, AHI
Number of subjects: 405
Study 31079124 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-adjusted for Asians and Caucasians
Number of subjects: 405
Study 28183331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib plus fulvestrant
Number of subjects: 97
Study 28183331 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 97
Study 28183331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib plus fulvestrant (FGF pathway-amplified subgroup)
Number of subjects: 97
Study 28183331 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (FGF pathway-amplified subgroup)
Number of subjects: 97
Study 25631454 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 27
Study 25631454 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 27
Study 23663288 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute VSI in compressions-only CPR
Number of subjects: 488
Study 23663288 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-minute VSI in compressions and ventilations
Number of subjects: 488
Study 23663288 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 488
Study 21827664 — intervention group
Group type: EXPERIMENTAL
Intervention: Black sesame meal (2.52 g capsules daily for 4 weeks)
Number of subjects: 30
Study 21827664 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (daily for 4 weeks)
Number of subjects: 30
Study 19846586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low scores on leadership dimension
Number of subjects: 930
Study 19846586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low emotionality
Number of subjects: 930
Study 19846586 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores on leadership
Number of subjects: 930
Study 19846586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low scores on caring and self‐assertiveness dimensions
Number of subjects: 930
Study 17298703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU retinol for < 12 months; 45,000 IU retinol for >= 12 months)
Number of subjects: 188
Study 17298703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 188
Study 17298703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 14612991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 41
Study 14612991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 11166780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized low-density lipoproteins (Ox-LDL) levels in patients with CSA
Number of subjects: 37
Study 11166780 — intervention group
Group type: COMPARATOR
Intervention: Control group (79 consecutive control patients)
Number of subjects: 37
Study 11166780 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Ox-LDL
Number of subjects: 37
Study 11166780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ox-LDL levels
Number of subjects: 37
Study 9782219 — intervention group
Group type: COMPARATOR
Intervention: Short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days)
Number of subjects: 61
Study 9782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days)
Number of subjects: 61
Study 8167656 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% carbohydrate, low carbonation (8%-C)
Number of subjects: 8
Study 8167656 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% carbohydrate, noncarbonated (8%-NC)
Number of subjects: 8
Study 8167656 — intervention group
Group type: COMPARATOR
Intervention: Water (0%-NC)
Number of subjects: 8
Study 3410606 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg i.v. methylepoxyproscillaridin (P35)
Number of subjects: 9
Study 3410606 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral methylepoxyproscillaridin (P35)
Number of subjects: 9
Study 30630108 — intervention group
Group type: EXPERIMENTAL
Intervention: iAmHealthy intervention (25-contact hour multicomponent intervention delivered over 8 months)
Number of subjects: 144
Study 30630108 — intervention group
Group type: EXPERIMENTAL
Intervention: iAmHealthy intervention
Number of subjects: 144
Study 30630108 — intervention group
Group type: COMPARATOR
Intervention: Monthly newsletter (control)
Number of subjects: 144
Study 28727701 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded placebo shockwave treatment
Number of subjects: 106
Study 28727701 — intervention group
Group type: COMPARATOR
Intervention: Unblinded placebo shockwave treatment
Number of subjects: 106
Study 25892151 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused intervention (WFI)
Number of subjects: 167
Study 25892151 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 167
Study 23153437 — intervention group
Group type: EXPERIMENTAL
Intervention: PlyD1 at 10 μg
Number of subjects: 100
Study 23153437 — intervention group
Group type: EXPERIMENTAL
Intervention: PlyD1 at 25 μg
Number of subjects: 100
Study 23153437 — intervention group
Group type: EXPERIMENTAL
Intervention: PlyD1 at 50 μg
Number of subjects: 100
Study 23153437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22216655 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan, 2% PVM/MA copolymer, 0.243% NaF, specially-designed silica)
Number of subjects: 117
Study 22216655 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.3% triclosan, 2% PVM/MA copolymer, 0.243% NaF in high cleaning silica base)
Number of subjects: 117
Study 22216655 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% NaF in silica base)
Number of subjects: 117
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI patients at admission
Number of subjects: 40
Study 19906505 — intervention group
Group type: COMPARATOR
Intervention: NSTEMI patients at admission
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers (SAA and WBC)
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC and SAA
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6
Number of subjects: 40
Study 19906505 — intervention group
Group type: EXPERIMENTAL
Intervention: Total incidence of major adverse clinical events (MACE)
Number of subjects: 40
Study 16488376 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg glatiramer acetate
Number of subjects: 1651
Study 16488376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glatiramer acetate
Number of subjects: 1651
Study 16488376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651
Study 15662998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigerian citrus honey
Number of subjects: 45
Study 11341138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program targeting physicians with recommendations to reduce PIPs
Number of subjects: 266
Study 11341138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 266
Study 11341138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with case conferences
Number of subjects: 266
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: CU (cuprophane) membrane
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: PS (polysulfone) membrane
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN (polyacrylonitrile) membrane
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: CU dialyzer (outlet)
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: CU (heparinized uremic blood samples)
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: PS (heparinized uremic blood samples)
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN (heparinized uremic blood samples)
Number of subjects: 10
Study 8995746 — intervention group
Group type: COMPARATOR
Intervention: Control (heparinized uremic blood samples)
Number of subjects: 10
Study 8995746 — intervention group
Group type: EXPERIMENTAL
Intervention: CU, PS, PAN membranes
Number of subjects: 10
Study 8302306 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 93
Study 8302306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 3734451 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mmol/day of KCl (Slow‐K, Ciba Geigy)
Number of subjects: 44
Study 3734451 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 44
Study 29750366 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (2 g daily oral dose)
Number of subjects: 70
Study 29750366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27358385 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg)
Number of subjects: 842
Study 27358385 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (1 mg)
Number of subjects: 842
Study 25065693 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Cherry Blossom Extract (CBE)
Number of subjects: 40
Study 25065693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saanen parent stock (SAPS)
Number of subjects: 0
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saanen F1 (SAF1)
Number of subjects: 0
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anglo-Nubian F1 (ANF1)
Number of subjects: 0
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anglo-Nubian parent stock (ANSP)
Number of subjects: 0
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anglo-Nubian parent stock (ANPS)
Number of subjects: 0
Study 21739132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saanen F1
Number of subjects: 0
Study 21739132 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 18976753 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 500
Study 18976753 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive ring
Number of subjects: 500
Study 18574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective CT angiography
Number of subjects: 60
Study 18574140 — intervention group
Group type: COMPARATOR
Intervention: Retrospective CT angiography
Number of subjects: 60
Study 18574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 16095058 — intervention group
Group type: EXPERIMENTAL
Intervention: IRCR
Number of subjects: 19
Study 16095058 — intervention group
Group type: EXPERIMENTAL
Intervention: CR
Number of subjects: 19
Study 16095058 — intervention group
Group type: COMPARATOR
Intervention: Enamel
Number of subjects: 19
Study 11803003 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa/Hib
Number of subjects: 200
Study 11803003 — intervention group
Group type: COMPARATOR
Intervention: DTPw/Hib
Number of subjects: 200
Study 10737366 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pentoxifiline (PTFL) administration
Number of subjects: 0
Study 10737366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTFL)
Number of subjects: 0
Study 9189781 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored, 6% sucrose drink containing 25 mmol/L NaCl (LNa(+)‐R)
Number of subjects: 6
Study 9189781 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored, 6% sucrose drink containing 50 mmol/L NaCl (HNa(+)‐R)
Number of subjects: 6
Study 9189781 — intervention group
Group type: COMPARATOR
Intervention: Flavored/artificially sweetened water (H2O‐R)
Number of subjects: 6
Study 1332356 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine‐adrenaline (pH = 6.1)
Number of subjects: 40
Study 1332356 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine‐adrenaline (pH = 7.5)
Number of subjects: 40
Study 1332356 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine‐adrenaline (pH = 6.1)
Number of subjects: 40
Study 1332356 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine‐adrenaline (pH = 7.4)
Number of subjects: 40
Study 1332356 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline (pH = 6.1)
Number of subjects: 40
Study 3872836 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (300 mg/day)
Number of subjects: 75
Study 3872836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg/d)
Number of subjects: 140
Study 29150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg/d)
Number of subjects: 140
Study 27362350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 50
Study 25436771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 ATA
Number of subjects: 60
Study 25436771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 2.0 ATA
Number of subjects: 60
Study 25436771 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 60
Study 21965226 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 12 weeks
Number of subjects: 250
Study 21965226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 20097780 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care (problem-solving therapy and/or antidepressant medication, telephone follow-up, systems navigation assistance)
Number of subjects: 387
Study 20097780 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (standard clinic care, depression educational pamphlets, community resource list)
Number of subjects: 387
Study 20097780 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care
Number of subjects: 387
Study 18339831 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Patients Programme (EPP) intervention
Number of subjects: 0
Study 18339831 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 0
Study 15758802 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.06%
Number of subjects: 70
Study 15758802 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05%
Number of subjects: 70
Study 12576246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of mifepristone
Number of subjects: 40
Study 12576246 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of mifepristone
Number of subjects: 40
Study 10382880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 400 mg moxifloxacin
Number of subjects: 12
Study 10382880 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 400 mg moxifloxacin
Number of subjects: 12
Study 8724874 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso‐esophageal probe
Number of subjects: 41
Study 8724874 — intervention group
Group type: EXPERIMENTAL
Intervention: pH of the esophageal content
Number of subjects: 41
Study 8724874 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of esophageal contents
Number of subjects: 41
Study 31918612 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation microbreak
Number of subjects: 199
Study 31918612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery microbreak
Number of subjects: 199
Study 31918612 — intervention group
Group type: COMPARATOR
Intervention: No break
Number of subjects: 199
Study 30232625 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 53
Study 30232625 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX™ (control)
Number of subjects: 53
Study 30232625 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™ and Fuji IX™
Number of subjects: 53
Study 28282743 — intervention group
Group type: EXPERIMENTAL
Intervention: Power (POW); 3 sets × 6 repetitions at 45%1RM × 3 min inter‐set rest
Number of subjects: 12
Study 28282743 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength (ST); 3 sets × 3 repetitions at 90%1RM × 3 min inter‐set rest
Number of subjects: 12
Study 28282743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP); 3 sets × 10 repetitions at 70%1RM × 1 min inter‐set rest
Number of subjects: 12
Study 27154301 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dynamics-based-high presence
Number of subjects: 135
Study 27154301 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dynamics-based-low presence
Number of subjects: 135
Study 27154301 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard social support
Number of subjects: 135
Study 27154301 — intervention group
Group type: COMPARATOR
Intervention: Individual control
Number of subjects: 135
Study 24719128 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4
Number of subjects: 54
Study 24719128 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 54
Study 24719128 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte
Number of subjects: 54
Study 21816681 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multilevel intervention with monthly on-site consultation from expert nurses
Number of subjects: 58
Study 21816681 — intervention group
Group type: COMPARATOR
Intervention: Attention control with monthly information about aging and physical assessment of elders
Number of subjects: 58
Study 17919894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day) added to metformin or sulphonylurea
Number of subjects: 250
Study 17919894 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of metformin (400mg) and glibenclamide (2.5 mg)
Number of subjects: 250
Study 15916993 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT + CRT magazines
Number of subjects: 1227
Study 15916993 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT magazines
Number of subjects: 1227
Study 15916993 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT magazines
Number of subjects: 1227
Study 15916993 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1227